Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis

Abstract

Down syndrome arises from chromosomal non-disjunction during gametogenesis, resulting in an additional chromosome. This anomaly presents with intellectual impairment, growth limitations, and distinct facial features. Positive correlation exists between maternal age, particularly in advanced cases, and the global annual incidence is over 200,000 cases. Early interventions, including first and second-trimester screenings, have improved DS diagnosis and care. The manifestations of Down syndrome result from complex interactions between genetic factors linked to various health concerns. To explore recent advancements in Down syndrome research, we focus on the integration of artificial intelligence (AI) and machine learning (ML) technologies for improved diagnosis and management. Recent developments leverage AI and ML algorithms to detect subtle Down syndrome indicators across various data sources, including biological markers, facial traits, and medical images. These technologies offer potential enhancements in accuracy, particularly in cases complicated by cognitive impairments. Integration of AI and ML in Down syndrome diagnosis signifies a significant advancement in medical science. These tools hold promise for early detection, personalized treatment, and a deeper comprehension of the complex interplay between genetics and environmental factors. This review provides a comprehensive overview of neurodevelopmental and cognitive profiles, comorbidities, diagnosis, and management within the Down syndrome context. The utilization of AI and ML represents a transformative step toward enhancing early identification and tailored interventions for individuals with Down syndrome, ultimately improving their quality of life.

The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain

“…Ongoing clinical studies have advanced our understanding of the behavioral domains in neuropsychiatric conditions and have sought their potential management [ 184 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 ]. Furthermore, computational strategies accelerate our advancement in comprehending their pathology, as well as in developing novel strategies for the management of neurological and psychiatric disorders, including neurotropic computer-assisted drug design [ 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 ]. Integrating these interdisciplinary approaches further adds impetus and optimizes strategies, including drug development research, leading to the testing and assessment of potential lead compounds.…”

Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry

“…Nevertheless, the outcomes of these treatments can vary depending on several factors [ 71 , 72 , 73 ]. This special issue features three articles that explore various aspects of cognition in individuals with SCZ [ 74 , 75 , 76 ]. The articles explored how cognition is affected by factors such as the onset and duration of psychosis, severity of symptoms, level of dissociation, and resistance to treatment.…”

“…Furthermore, they examined the application of artificial intelligence as a means of improving the diagnosis and treatment of SCZ and related conditions. Koul et al presented a review of Down syndrome (DS), a genetic disorder that causes intellectual and physical impairments [ 76 ]. This work discusses how artificial intelligence and machine learning can help diagnose and treat DS by analyzing various data sources.…”